Results 121 to 130 of about 16,311 (178)
Subacute cutaneous lupus erythematosus secondary to intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy: A case report. [PDF]
JAAD Case RepSmith K, Nathoo R, Foss MG.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 1999
Valsartan/hydrochlorothiazide (HCTZ) combines an angiotensin II AT1 receptor blocker with a thiazide diuretic to produce additive blood pressure reductions without major effects on heart rate. HCTZ did not significantly alter valsartan pharmacokinetics; during combination therapy, HCTZ pharmacokinetics differed from those seen with HCTZ monotherapy. In
H D, Langtry, K J, McClellan
openaire +2 more sources
Valsartan/hydrochlorothiazide (HCTZ) combines an angiotensin II AT1 receptor blocker with a thiazide diuretic to produce additive blood pressure reductions without major effects on heart rate. HCTZ did not significantly alter valsartan pharmacokinetics; during combination therapy, HCTZ pharmacokinetics differed from those seen with HCTZ monotherapy. In
H D, Langtry, K J, McClellan
openaire +2 more sources
Pneumonitis and Hydrochlorothiazide
Annals of Internal Medicine, 1973Excerpt To the editor: We read with great interest the report of hydrochlorothiazide-induced allergic pneumonitis by Beaudry and Laplante (Ann Intern Med78:251-253, 1973).
ARTHUR KAUFMAN +4 more
openaire +2 more sources
Hydrolysis of Hydrochlorothiazide
Journal of Pharmaceutical Sciences, 1969J A, Mollica, C R, Rehm, J B, Smith
openaire +2 more sources